Phosphatidic Acid (PA).

Phosphatidic acid binds mTOR directly at the FRB domain while leucine signals through the Sestrin and Rag pathway to the same complex. The two arrive at mTORC1 by separate routes, which is why they are formulated together.

Phosphatidic acid raises the anabolic signal but supplies no amino acids, so a rapidly absorbed protein provides the building material the signal calls for. Signalling without substrate has nothing to build from.

Phosphatidic acid pushes the synthesis side through mTORC1 while HMB acts mainly on the breakdown side through ubiquitin-proteasome signalling. Net balance depends on both arms.

Creatine raises phosphocreatine available for repeated high intensity work while phosphatidic acid acts on the signalling response to that work. They sit at different points of the same training adaptation.

An mTORC1 signal raised by phosphatidic acid can only translate into new protein if the full set of essential amino acids is present. EAAs remove the substrate ceiling.

Phosphatidic acid is the central branch point of glycerophospholipid synthesis and feeds into phosphatidylcholine through the CDP-diacylglycerol and Kennedy routes. Supplying both loads precursor and product of the same pathway.

Soy lecithin is the raw material phosphatidic acid is enzymatically produced from, and lecithin phospholipids help disperse it in the gut. This is why the two frequently appear on the same label.

Phosphatidic acid is the branch point for phosphatidylinositol synthesis: it is activated to CDP-diacylglycerol, which then condenses with free inositol. Cells that run short of phosphatidic acid run short of the substrate for that step. A 2026 yeast study in the candidate set traces exactly that dependency, and it is yeast rather than human data.

Phosphatidic acid and phosphatidylcholine sit on the same lipid pathway. Phosphatidic acid is dephosphorylated to diacylglycerol, which accepts a choline head group from CDP-choline to form phosphatidylcholine. Dietary choline supplies that head group, so the two nutrients feed one membrane-building sequence from different ends.

CDP-choline is the activated donor that transfers choline onto the diacylglycerol derived from phosphatidic acid. Supplying the donor and supplying the lipid backbone address two different rate-limiting points in the same reaction. This is pathway logic rather than a tested combination in people.

Both are anionic membrane phospholipids and both are reachable from the CDP-diacylglycerol and base-exchange routes that phosphatidic acid feeds. Formulators pair them because they occupy adjacent positions in the same lipid family rather than because a trial measured the pair. Marker-level membrane chemistry, not a measured outcome.

Serine is the head group installed during phosphatidylserine formation, a step downstream of the CDP-diacylglycerol pool that phosphatidic acid supplies. Head group and backbone are separate inputs to the same product. No human combination data exists.

Alpha-GPC is a deacylated phosphatidylcholine metabolite and a choline source that re-enters phospholipid synthesis. Paired with phosphatidic acid it contributes to the same membrane phospholipid pool from the choline side. Mechanistic pairing only.

Phosphatidylcholine can also be made by three successive methylations of phosphatidylethanolamine, and betaine keeps the methyl supply for that route running through homocysteine remethylation. Where methyl donors are short, the phospholipid pool that phosphatidic acid feeds is harder to maintain. This is upstream support, not a measured effect on muscle.

Phosphatidic acid is studied for its interaction with mTOR signalling, while a slowly digested dairy protein supplies the amino acids that the same signalling drives into new muscle protein. Signal without substrate does little. The stored whey pairing follows the same logic with a faster protein.

Long-chain omega-3 fatty acids are incorporated into the acyl positions of membrane phospholipids, including phosphatidic acid and its products, which changes membrane fluidity and the local lipid environment where signalling proteins dock. That is a compositional change, not a demonstrated additive strength effect.

Phosphatidic acid is a lipid, and lipid uptake depends on micelle formation with bile salts and other fats. Taking it with a fat source, including medium-chain triglycerides, follows ordinary practice for lipophilic ingredients. No absorption study of the specific pair exists in the candidate set.

Lecithin is the industrial starting material most phosphatidic acid is made from, and residual lecithin phospholipids often ride along in the finished powder. Adding lecithin supplies a mixed phospholipid background rather than more phosphatidic acid. Read the specification, since the two are not interchangeable.

Phospholipids carrying polyunsaturated acyl chains oxidise readily, and tocopherols are the chain-breaking antioxidants that sit in the membrane and in the finished oil. This protects the ingredient and the membrane lipid pool. It is stability and redox chemistry, not a performance claim.

Vitamin D receptor signalling in skeletal muscle influences the anabolic response to loading, which is the same broad process phosphatidic acid is studied against. The overlap is at the level of signalling biology and status, not a trial of the two together. Vitamin D status is a marker here, not an outcome.